Source: United Daily News via Health Business Division · 2025-08-22
Headline Summary:
Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) and their supporters gathered at the “Seize the Treatment Window, Reclaim Your Vision!” support event organized by the Taiwan Neuro-Immunology & Movement Education Association. The event fostered supportive dialogue and emphasized the urgency of timely treatment.
Event Highlights and Key Messages
Early Diagnosis & Treatment Are Vital:
Dr. Nai-Wen Tsai from Chang Gung Memorial Hospital Kaohsiung underscored the importance of timely diagnosis and treatment in controlling NMOSD. Psychiatrist Dr. Hung Chi-Fa addressed the emotional toll NMOSD patients often face—anxiety, uncertainty, and self-doubt—and stressed the need for psychological support to enhance overall well-being.
Healing through Horticultural Therapy:
Participants experienced a calming horticultural session led by therapists Chia-Hua Ho and Jin-Feng Hsu. One attendee shared: “Living with a chronic illness is arduous. These gentle, healing activities reminded us we’re not alone.” The organizers pledged to continue supporting patient advocacy and education.
NMOSD: A Rapidly Disabling Autoimmune Disease:
NMOSD is a relapsing, rare autoimmune disorder often affecting women, leading to recurrent inflammation in the optic nerve and spinal cord. A 2024 study cited by Clinical & Translational Neurology reports NMOSD patients face a threefold higher mortality rate, with a third dying due to disability caused by relapse. Early medical intervention is critical for long-term disease control.
Improved Prognosis, but Access Remains Limited:
Advances in diagnosis, such as autoantibody testing, have enabled better discrimination between NMOSD and multiple sclerosis (MS). Monoclonal antibody treatments have dramatically lowered five-year mortality rates from 30% to 2%. Still, particularly in severe cases, timely access to these effective therapies remains essential to prevent disability and preserve daily function.
Drug Coverage Policy Needs Reform:
Currently, National Health Insurance (NHI) requires patients experience two relapses within a year plus functional decline to qualify for coverage. Dr. Tsai criticized this threshold, noting that some patients who relapse just outside this window—despite severe disease—are excluded. Of the 92 patients covered by December 2024, fewer than 20% of those in dire need received access. Looser criteria, such as allowing eligibility when two relapses occur within two years, could better align with clinical realities.
The Medical Community and Lawmakers Lend Support:
In a press conference organized by NMOSD patient groups, several legislators—including Wang Yu-Min, Chen Ching-Hui, Huang Shan-Shan, and Su Chiao-Hui—called for reform. They emphasized that no patient deserves to worsen while waiting for treatment. A recent Legislative Yuan health committee session echoed this urgency, urging Bolstered insurance access to improve care equity.
Hidden Psychological Impact on Patients:
Over 80% of NMOSD patients are women in their prime caregiving years. The unpredictable nature of relapses often triggers feelings of guilt, fear, and emotional conflict. Dr. Hung highlighted that around half of these patients also experience depression, anxiety, or sleep disturbances—making long-term mental health support imperative.
Conclusion: Bridging the Gap Between Clinical Advancements and Health Equity
Medical breakthroughs have transformed NMOSD outcomes. Yet the current NHI coverage structure fails to fully match these advances, leaving many patients with biological and emotional burdens. The path forward requires policy reform that puts patient needs first—ensuring timely access to effective therapies and holistic care. Only then can NMOSD patients be assured the life and support they urgently need.
